Profile
| Role | Director, 10% Owner |
|---|---|
| Notability | 20/100 |
Board memberships
- Biomea Fusion, Inc.
- MoonLake Immunotherapeutics
- BridgeBio Oncology Therapeutics, Inc.
Updated Jul 16, 2026
Chen Bihua has filed 2 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $8.00M. Lifetime open-market sales: $46.87M.
| Role | Director, 10% Owner |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | BBOT | BridgeBio Oncology Therapeutics, Inc. | J — Other acquisition / disposition | 130.9K | $0.00 | |
| 2026-07-06 | BBOT | BridgeBio Oncology Therapeutics, Inc. | J — Other acquisition / disposition | 1.70M | $0.00 | |
| 2026-07-06 | BBOT | BridgeBio Oncology Therapeutics, Inc. | J — Other acquisition / disposition | 2.69M | $0.00 | |
| 2026-07-06 | BBOT | BridgeBio Oncology Therapeutics, Inc. | J — Other acquisition / disposition | 4.53M | $0.00 | |
| 2026-01-29 | HLXC | Helix Acquisition Corp. III | P — Open-market purchase | 800.0K | $10.00 | $8.00M |
| 2026-01-29 | HLXC | Helix Acquisition Corp. III | A — Grant or award | 497.5K | $10.00 | $4.97M |
| 2026-01-26 | HLXC | Helix Acquisition Corp. III | A — Grant or award | 497.5K | $10.00 | $4.97M |
| 2025-09-29 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 5.8K | $6.96 | $41K |
| 2025-09-29 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 2.80M | $6.61 | $18.51M |
| 2025-09-29 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 3.39M | $7.58 | $25.70M |
| 2025-09-29 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 232.5K | $8.40 | $1.95M |
| 2025-09-29 | MLTX | MoonLake Immunotherapeutics | S — Open-market sale | 70.7K | $9.38 | $664K |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 284.6K | — | |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 1.76M | — | |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 1.91M | — | |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 5.60M | $10.72 | $60.00M |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 639.1K | $10.72 | $6.85M |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | A — Grant or award | 760.5K | $10.72 | $8.15M |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | D — Derivative transaction | 152.9K | $0.00 | |
| 2025-08-11 | BBOT | BridgeBio Oncology Therapeutics, Inc. | M — Option exercise | 4.17M | — |
Chen Bihua is a corporate insider — currently tracked as Director, 10% Owner of BridgeBio Oncology Therapeutics, Inc. (BBOT). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($8.00M) and 5 open-market sales ($46.87M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chen Bihua profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.